- Home
- GUT vs MREO Comparison
GUT vs MREO Comparison
Compare GUT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUT
- MREO
- Stock Information
- Founded
- GUT 1999
- MREO 2015
- Country
- GUT United States
- MREO United Kingdom
- Employees
- GUT N/A
- MREO N/A
- Industry
- GUT Trusts Except Educational Religious and Charitable
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- GUT Finance
- MREO Health Care
- Exchange
- GUT Nasdaq
- MREO Nasdaq
- Market Cap
- GUT 475.6M
- MREO 438.8M
- IPO Year
- GUT N/A
- MREO N/A
- Fundamental
- Price
- GUT $5.93
- MREO $2.94
- Analyst Decision
- GUT
- MREO Strong Buy
- Analyst Count
- GUT 0
- MREO 5
- Target Price
- GUT N/A
- MREO $7.60
- AVG Volume (30 Days)
- GUT 176.3K
- MREO 1.3M
- Earning Date
- GUT 01-01-0001
- MREO 08-12-2025
- Dividend Yield
- GUT 10.93%
- MREO N/A
- EPS Growth
- GUT N/A
- MREO N/A
- EPS
- GUT N/A
- MREO N/A
- Revenue
- GUT N/A
- MREO N/A
- Revenue This Year
- GUT N/A
- MREO N/A
- Revenue Next Year
- GUT N/A
- MREO $52.34
- P/E Ratio
- GUT N/A
- MREO N/A
- Revenue Growth
- GUT N/A
- MREO N/A
- 52 Week Low
- GUT $4.60
- MREO $1.58
- 52 Week High
- GUT $7.38
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- GUT 71.16
- MREO 62.21
- Support Level
- GUT $5.76
- MREO $2.77
- Resistance Level
- GUT $5.85
- MREO $3.05
- Average True Range (ATR)
- GUT 0.07
- MREO 0.17
- MACD
- GUT 0.00
- MREO 0.00
- Stochastic Oscillator
- GUT 99.81
- MREO 75.56
About GUT Gabelli Utility Trust (The)
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).